Search Results

You are looking at 71 - 80 of 2,667 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence

Gary H. Lyman

The prophylactic use of myeloid growth factors reduces the risk of chemotherapy-induced neutropenia and its complications, including febrile neutropenia and infection-related mortality. Perhaps most importantly, the prophylactic use of colony-stimulating factors (CSFs) has been shown to reduce the need for chemotherapy dose reductions and delays that may limit chemotherapy dose intensity, thereby increasing the potential for prolonged disease-free and overall survival in the curative setting. National surveys have shown that the majority of patients with potentially curable breast cancer or non-Hodgkin's lymphoma (NHL) do not receive prophylactic CSF support. In this issue, the National Comprehensive Cancer Network presents guidelines for the use of myeloid growth factors in patients with cancer. These guidelines recommend a balanced clinical evaluation of the potential benefits and harms associated with chemotherapy to define the treatment intention, followed by a careful assessment of the individual patient's risk for febrile neutropenia and its complications. The decision to use prophylactic CSFs is then based on the patient's risk and potential benefit from such treatment. The routine prophylactic use of CSFs in patients receiving systemic chemotherapy is recommended in patients at high risk (>20%) of developing febrile neutropenia or related complications that may compromise treatment. Where compelling clinical indications are absent, the potential for CSF prophylaxis to reduce or offset costs by preventing hospitalization for FN should be considered. The clinical, economic, and quality of life data in support of these recommendations are reviewed, and important areas of ongoing research are highlighted.

Full access

Diagnostic and Treatment Considerations When Newly Diagnosed Breast Cancer Coincides With Pregnancy: A Case Report and Review of Literature

Lauren Nye, Timothy K. Huyck, and William J. Gradishar

maternal grandmother, who was diagnosed and treated at 55 years of age. Review of systems was positive for intermittent headaches consistent with previous self-limiting migraines and occasional nausea without emesis, which had been diminishing in frequency

Full access

Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature

Ivan Lolli, Anna Maria Valentini, Angela Dalia Ricci, and Raffaele Armentano

. References 1. Vangipuram R , Tyring SK . Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant . Int J Dermatol 2019 ; 58 : 538 – 542 . 2. Grayson W , Pantanowitz L . Histological variants of

Full access

Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature

Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas

reviewed by the Perthera molecular tumor board, the one who most closely resembled our current patient experienced a partial response to an NTRK inhibitor (entrectinib) and, at the time of study publication, had continued on therapy for >1 year. 9

Full access

CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review

David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal

literature review was conducted to understand how patients with early-stage MCC are treated and assess efficacy and safety of current therapies. METHODS: Embase and PubMed were used to identify publications from January 2014 to October 2019, capturing

Full access

HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators

Erin Comerford, Lindsey Norcross, Medha Sasane, Ying Zheng, and Ari Gnanasakthy

reporting of PROs in clinical trials remains suboptimal and most product labels do not mention patient experience data. The aim of this review is to better understand potential issues that may prevent PRO data from being included in product labeling

Full access

CLO24-068: The Role of Obesity in Influencing Patient Survival in Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis.

Chalothorn Wannaphut, Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, and Pakin Lalitnithi

good sign. Therefore, the primary aim was to conduct a comprehensive review and meta-analysis to look into the prognostic importance of BMI in patients with mRCC receiving ICIs. Objective : The main aim of the present systematic review and meta

Full access

EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review

Brenda Santellano, Rashi Agrawal, Gabriela Duchesne, Muhannad Sharara, E. Andrew Balas, Gagan Agrawal, Meng-Han Tsai, Asha Nayak-Kapoor, and Jorge E. Cortes

between SDOH and survival in patients with GI cancer in the United States. Methods: We perform a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Independent authors searched

Full access

HSR24-139: Patient-Reported Outcome Measures Used in Patients With Chronic Phase–Chronic Myeloid Leukemia: A Systematic Review of the Literature

Kathryn E. Flynn, Lovneet Saini, Aditi Kataria, Kejal Jadhav, Daisy Yang, and David Wei

the PRO measures used. A systematic literature review was conducted to identify and summarize the evidence on PRO measures used for patients with CML in the first-line (1L) setting. Methods: In accordance with PRISMA guidelines, the Embase database

Full access

Long-Term Outcomes of Myeloid Growth Factor Treatment

Gary H. Lyman and David C. Dale

Controlled Trials of Long-Term Outcomes A systematic review recently reported on randomized controlled trials in adult patients with solid tumors or lymphoma undergoing systemic chemotherapy with or without primary G-CSF support with a follow-up of at least